EPCAM Gene

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Peter Tang	+ 573 word(s)	573	2020-12-30 02:38:19	\|
2	title change	Peter Tang	Meta information modification	573	2021-01-04 05:17:49	\|

This entry is adapted from the peer-reviewed paper https://medlineplus.gov/genetics/gene/epcam

Epithelial cell adhesion molecule

genes

1. Normal Function

The EPCAM gene provides instructions for making a protein known as epithelial cellular adhesion molecule (EpCAM). This protein is found in epithelial cells, which are the cells that line the surfaces and cavities of the body. The EpCAM protein is found spanning the membrane that surrounds epithelial cells, where it helps cells stick to one another (cell adhesion). In addition, the protein in the cell membrane can be cut at a specific location, releasing a piece called the intracellular domain (EpICD), which helps relay signals from outside the cell to the nucleus of the cell. EpICD travels to the nucleus and joins with other proteins, forming a group (complex) that regulates the activity of several genes that are involved in many cell processes, including growth and division (proliferation), maturation (differentiation), and movement (migration), all of which are important processes for the proper development of cells and tissues.

2. Health Conditions Related to Genetic Changes

2.1. Lynch syndrome

Certain mutations in the EPCAM gene are associated with Lynch syndrome, a condition that increases the risk of developing many types of cancer, particularly cancers of the large intestine (colon) and the rectum (collectively called colorectal cancer). These mutations account for up to 3 percent of Lynch syndrome cases. On chromosome 2, the EPCAM gene lies next to another gene called MSH2. Each gene provides instructions for making an individual messenger RNA (mRNA), which serves as the genetic blueprint for making the protein. The EPCAM gene mutations involved in Lynch syndrome remove a region that signals the end of the gene, which leads to formation of a long mRNA that includes both EPCAM and MSH2.

For unknown reasons, these EPCAM gene mutations cause the MSH2 gene to be turned off (inactivated) by a mechanism known as promoter hypermethylation. The promoter is a region of DNA near the beginning of the gene that controls gene activity (expression). Hypermethylation occurs when too many small molecules called methyl groups are attached to the promoter region. The extra methyl groups attached to the MSH2 promoter reduce the expression of the MSH2 gene, which means that less protein is produced in epithelial cells.

The MSH2 protein plays an essential role in repairing errors in DNA; loss of this protein prevents proper DNA repair, and errors accumulate as the cells continue to divide. These errors can lead to uncontrolled cell growth and increase the risk of cancer.

2.2. Other disorders

Mutations in the EPCAM gene can also cause congenital tufting enteropathy. This condition is characterized by abnormal development of epithelial cells in the intestines. In this condition, the villi, which are small finger-like projections that line the small intestine, are abnormal. In particular, they have "tufts" of extra epithelial cells on their tips. Normally, these projections provide a greatly increased surface area to absorb nutrients. The altered villi are less able to absorb nutrients and fluids than normal tissue, which causes life-threatening diarrhea and poor growth. Congenital tufting enteropathy develops in newborns within days of birth and lasts throughout life.

People with congenital tufting enteropathy have two copies of the altered EPCAM gene in each cell. These mutations lead to an absence of functional EpCAM protein. The resulting loss of EpICD signaling leads to abnormal development of intestinal epithelial cells, causing congenital tufting enteropathy.

3. Other Names for This Gene

EGP-2
EGP34
EGP40
Ep-CAM
epithelial cell adhesion molecule precursor
epithelial glycoprotein 314
human epithelial glycoprotein-2
TACST-1
TACSTD1
TROP1
tumor-associated calcium signal transducer 1

References

Kohlmann W, Gruber SB. Lynch Syndrome. 2004 Feb 5 [updated 2018 Apr 12]. In:Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A,editors. GeneReviews® [Internet]. Seattle (WA): University of Washington,Seattle; 1993-2020. Available from http://www.ncbi.nlm.nih.gov/books/NBK1211/ Citation on PubMed
Kuiper RP, Vissers LE, Venkatachalam R, Bodmer D, Hoenselaar E, Goossens M,Haufe A, Kamping E, Niessen RC, Hogervorst FB, Gille JJ, Redeker B, Tops CM, van Gijn ME, van den Ouweland AM, Rahner N, Steinke V, Kahl P, Holinski-Feder E,Morak M, Kloor M, Stemmler S, Betz B, Hutter P, Bunyan DJ, Syngal S, Culver JO,Graham T, Chan TL, Nagtegaal ID, van Krieken JH, Schackert HK, Hoogerbrugge N,van Kessel AG, Ligtenberg MJ. Recurrence and variability of germline EPCAMdeletions in Lynch syndrome. Hum Mutat. 2011 Apr;32(4):407-14. doi:10.1002/humu.21446. Epub 2011 Mar 1. Citation on PubMed
Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG,van Kessel AG, Yuen ST, van Krieken JH, Leung SY, Hoogerbrugge N. Heritablesomatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet. 2009 Jan;41(1):112-7. doi:10.1038/ng.283. Epub 2008 Dec 21. Citation on PubMed
Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P,Baeuerle PA, Munz M, Gires O. Nuclear signalling by tumour-associated antigenEpCAM. Nat Cell Biol. 2009 Feb;11(2):162-71. doi: 10.1038/ncb1824. Epub 2009 Jan 11. Citation on PubMed
Niessen RC, Hofstra RM, Westers H, Ligtenberg MJ, Kooi K, Jager PO, de Groote ML, Dijkhuizen T, Olderode-Berends MJ, Hollema H, Kleibeuker JH, Sijmons RH.Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause ofLynch syndrome. Genes Chromosomes Cancer. 2009 Aug;48(8):737-44. doi:10.1002/gcc.20678. Citation on PubMed
Schnell U, Kuipers J, Mueller JL, Veenstra-Algra A, Sivagnanam M, Giepmans BN.Absence of cell-surface EpCAM in congenital tufting enteropathy. Hum Mol Genet.2013 Jul 1;22(13):2566-71. doi: 10.1093/hmg/ddt105. Epub 2013 Mar 5. Citation on PubMed or Free article on PubMed Central
Sivagnanam M, Mueller JL, Lee H, Chen Z, Nelson SF, Turner D, Zlotkin SH,Pencharz PB, Ngan BY, Libiger O, Schork NJ, Lavine JE, Taylor S, Newbury RO,Kolodner RD, Hoffman HM. Identification of EpCAM as the gene for congenitaltufting enteropathy. Gastroenterology. 2008 Aug;135(2):429-37. doi:10.1053/j.gastro.2008.05.036. Epub 2008 May 15. Citation on PubMed or Free article on PubMed Central
Tamura K, Kaneda M, Futagawa M, Takeshita M, Kim S, Nakama M, Kawashita N,Tatsumi-Miyajima J. Correction to: Genetic and genomic basis of the mismatchrepair system involved in Lynch syndrome. Int J Clin Oncol. 2019 Sep;24(9):1012. doi: 10.1007/s10147-019-01515-w. Citation on PubMed

©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Genetics & Heredity

Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Peter Tang

View Times: 376

Entry Collection: MedlinePlus

Update Date: 04 Jan 2021

Table of Contents

Video Upload Options

Confirm